gastric cancer,colorectal cancer,lung cancer,ovarian cancer,cervical cancer and brest cancer
Conditions
Interventions
Administraion of irinotecan is twice for 4 weeks . Adjusted dosage is determined from 100or125 mg/sqm in the heterozygous group .
Sponsors
kobe University Hospital and Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically confirmed cancer 2)Testing confirmed UGT1A1*28 and UGT1A1*6 polymorphisms 3)Having prior chemotherapy as standard regimens 4)No prior irinotecan containing treatment 5)Age:>=20 years old at wiritten informed concent 6)PS(ECOG):0 to 1
Exclusion criteria
Exclusion criteria: 1)History of serious drug allergy 2)Active concomitant malignancy 3)Prior extensively irradiation for abdominal or bowel bone marrow 4)Symptomatic brain metastasis 5)Systemic continual use of steroids 6)Active infection 7)Persistent diarrhea (watery stool) 8)Intestinal obstraction or paralytic ileus 9)Interstitial pneumonia or pulmonary fibrosis 10)Massive pleural, pericardial effusion or asites that required drainage 11)Need to treatment with atazanavir sulfate 12)Uncontrolled diabetes mellitus 13)Heart disease deemed to unacceptable by diagnosis of cardiogram within the previous 28 days before enrollment 14)Psychological disease deemed to unacceptable for inclusion to the study 15)Pregnant or lactating women, couple wishing pregnant or no mind of prevent pregnancy 16)Other concominant medical condition deemed to inadequate for inclusion to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adverse events | — |
Countries
Japan
Contacts
Public ContactHideo Tomioka
kobe University Hospital and Graduate School of Medicine Medical Oncology,Department of Medicine
Outcome results
None listed